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2422Fibroblast growth factor (FGF)-
23 is a phosphatonin, a circu-
lating endocrine regulator of
mineral metabolism that rises in
the earliest stages of renal impair-
ment (1–3). Markedly elevated
levels of FGF-23, observed in
patients with moderate-to-severe
chronic kidney disease (CKD),
are associated with an increased
risk of mortality (4,5). Data also
suggest that FGF-23 levels at
the higher end of the range seen
within the general population
may be associated with an in-
creased risk of cardiovascular
events in patients at risk for or
with stable ischemic heart dis-
ease (SIHD) (6–10). However,
the extent to which FGF-23 is a
signiﬁcant predictor of cardio-
vascular events independent of
clinical comorbidities, conven-
tional markers of renal function,
and established cardiovascular
biomarkers is unknown. Further-
more, whereas biomarkers of re-duced renal function identify patients with SIHD who derive
greater beneﬁt from angiotensin-converting enzyme (ACE)
inhibitor therapy (11,12), whether levels of FGF-23 can do
the same or better remains untested. Therefore, we tested
the hypotheses that in patients with SIHD, higher levels of
FGF-23 were associated with an increased risk of cardiovas-
cular events and identiﬁed patients who derived greater
clinical beneﬁt from ACE inhibition.Methods
Study design and participants. The PEACE (Prevention
of Events with Angiotensin-Converting Enzyme) Trial was
a randomized trial of trandolapril versus placebo in 8,290
participants age 50 years with SIHD, left ventricular
ejection fraction >40%, and serum creatinine 2.0 mg/dln-Coulter, Nanosphere, Ortho-Clinical Di-
, Astra-Zeneca, Bristol-Myers-Squibb, Daiichi
zer, Sanoﬁ-Aventis, and Takeda; grants and
i Lilly, Gilead, Johnson & Johnson, Merck &
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land has received grants, personal fees, and
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r on patents awarded to Brigham and Women’sthat enrolled patients from November 1996 through June
2000 (13,14). All participants from the United States and
Canada were eligible for biospecimen sampling at the
discretion of each clinical center, and approximately half
agreed to participate. All participants provided written
informed consent, and this study was approved by the
relevant institutional review boards. The current analysis
included all patients who had an enrollment blood sample
available for measurement of FGF-23 (n ¼ 3,627). There
were no clinically relevant differences between patients
included in the substudy and the overall trial population
(Online Table 1).
Biomarkers. FGF-23 levels were measured with a well-
established C-terminal human enzyme-linked immuno-
absorbent assay (Immunotopics, San Clemente, California)
(15) in the Thrombolysis in Myocardial Infarction (TIMI)
Clinical Trials Laboratory (Boston, Massachusetts) as
detailed in the supplemental Methods section in the Online
Appendix. In adults with preserved renal function, normal
values for this assay are 55  50 reference units (RU)/ml
(15). Baseline levels of the N-amino terminal fragment of
the prohormone B-type natriuretic peptide (NT-proBNP),
cardiac troponin T measured with the high-sensitivity assay
(hs-cTnT), C-reactive protein measured with a highly sen-
sitive assay (hs-CRP), midregional pro-atrial natriuretic
peptide, midregional pro-adrenomedullin, C-terminal pro-
endothelin-1, estimated glomerular ﬁltration rate
(eGFR) using the Modiﬁcation of Diet in Renal Disease
equation (16), cystatin C, and urinary albumin to creatinine
ratio (ACR) have been determined in this population pre-
viously (12,17–21). All biochemical testing was performed
by study personnel who were unaware of the clinical
outcome and treatment assignment.
Endpoints. On the basis of prior data regarding the pre-
dictive ability of FGF-23 (6,7), the primary outcome of
this analysis was the composite of cardiovascular death
or hospitalization for heart failure. Additionally, we ex-
plored other major adverse cardiovascular events that had
been part of the primary endpoint for the parent PEACE
trial, including myocardial infarction (MI), stroke, and
coronary revascularization. All clinical events were docu-
mented and adjudicated before this biomarker was
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2423Statistical analyses. Participants were separately divided
into quartiles according to their baseline FGF-23 levels and
descriptive analyses of baseline characteristics were per-
formed (see supplemental Methods section in the Online
Appendix). Cumulative event rates were calculated across
quartiles of FGF-23 with the Kaplan-Meier method and
compared by use of a trend test. Cumulative event rates were
also calculated stratifying patients on the basis of FGF-23
levels and established biomarkers of renal function, specif-
ically, eGFR, cystatin C (using a cut point of the top
quartile, 0.91 mg/l, which also approximates the top 2.5
percentile of the normal reference range [22]), and urinary
ACR (using sex-speciﬁc cut points of 25 mg/mg in women
and 17 mg/mg in men to deﬁne microalbuminuria as
previously described [18]).
The association between FGF-23 levels and outcomes
was estimated among placebo-assigned patients using
Cox proportional-hazards models to derive hazard ratios
(HR) and 95% conﬁdence intervals (CI) for elevation in
FGF-23 levels. Models were adjusted for the following
clinical risk factors: age, sex, weight, history of hypertension,
history of diabetes mellitus, current tobacco use, prior MI,
prior coronary revascularization, systolic blood pressure,
eGFR, and left ventricular ejection fraction. Models
containing the aforementioned clinical variables were then
also adjusted for 2 additional biomarkers of renal function:
cystatin C and urinary ACR. Further adjustment to the
described clinical and renal models was also performed
by adding the established and novel biomarkers delineated
in the preceding text under Biomarkers. The incremental
performance of FGF-23 was evaluated by calculating chan-
ges in the C-statistic, integrated discrimination improve-
ment, and category-free net reclassiﬁcation improvement
metrics (23).Table 1 Baseline Characteristics by FGF-23 Quartiles in the Placebo
Quartiles
1
(<38.81; N ¼ 454)
2
(38.81–50.05; N ¼ 454)
Age (yrs) 62.0  7.7 63.8  8.1
Female 48 (10.6) 53 (11.7)
Weight (kg) 82.5  14.2 84.6  15.2
Hypertension 184 (40.5) 198 (43.6)
Current tobacco use 65 (14.3) 48 (10.6)
Diabetes mellitus 58 (12.8) 62 (13.7)
Prior MI 276 (60.8) 270 (59.5)
Prior PCI or CABG 331 (72.9) 306 (67.4)
SBP (mm Hg) 131.8  16.4 131.9  15.9
DBP (mm Hg) 78.4  9.7 78.6  9.9
eGFR (mL/min/1.73 m2) 81.3  18.5 80.7  19.7
Apo B (mg/dl) 106.0  23.6 106.3  22.2
Apo A1 (mg/dl) 139.6  23.7 137.7  25.5
LVEF (%) 58.3  9.4 58.6  9.9
Values are mean  SD or n (%). Plasma FGF-23 concentrations are reported in reference units (RU)/ml
Apo ¼ apolipoprotein; CABG ¼ coronary artery bypass grafting; DBP ¼ diastolic blood pressure; eGF
ejection fraction; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; SBP ¼ systolicTo determine whether FGF-23 levels could be used to
identify patients in whom ACE inhibition resulted in
greater clinical beneﬁt, hazard ratios for the effect of tran-
dolapril on the risk of cardiovascular death or heart failure
were estimated in patients stratiﬁed by FGF-23 level. To
test for statistically signiﬁcant effect modiﬁcation, a Cox
proportional-hazards model was created that included a term
for trandolapril, a term for FGF-23 risk category, and an
interaction term. Further subcategorization was done by
additional stratiﬁcation using eGFR (60 or <60 ml/min/
1.73 m2) according to standard criteria for deﬁning advanced
CKD (24), and a recently developed multimarker score (21).
All p values were 2-sided and values of p < 0.05 were
considered to be statistically signiﬁcant. STATA/EC
(version 12.1, STATA Corp, College Station, Texas) and R
(version 2.12.1, R Foundation for Statistical Computing,
Vienna, Austria) were used for all analyses.Results
Baseline characteristics. Among the 3,627 participants with
a baseline measurement, the median level of FGF-23 was 50.6
RU/ml (interquartile range, 38.7 to 69.9). The distribution of
FGF-23 levels was similar to that in a healthy population
(adults, 55  50 RU/ml [15]), but lower than in patients with
stages 2 through 4 CKD (median, 145.5 RU/ml; interquartile
range, 95.8 to 239.1) (5). The baseline characteristics of pla-
cebo patients according to quartile of FGF-23 are shown in
Table 1. In general, higher baseline levels of FGF-23 were
associated with older age, female sex, hypertension, diabetes
mellitus, current tobacco use, and reduced eGFR, but with a
lower rate of prior MI. The correlation at baseline between
FGF-23 and established or experimental markers of renal
function and cardiovascular risk was moderate to weak, withArm
of FGF-23 (RU/ml)
p Value
for Trend*
3
(50.06–70.20; N ¼ 454)
4
(>70.20; N ¼ 453)
64.9  8.3 65.7  8.4 <0.0001
87 (19.2) 132 (29.1) <0.0001
83.5  16.1 84.5  17.0 0.47
206 (45.4) 226 (49.9) 0.004
68 (15.0) 99 (21.9) 0.0003
78 (17.2) 89 (19.7) 0.002
261 (57.5) 240 (53.0) 0.014
340 (74.9) 347 (76.6) 0.047
135.3  17.4 134.8  17.5 0.001
78.9  10.6 77.3  10.5 0.18
76.8  17.9 74.4  20.8 <0.0001
107.0  21.4 108.5  25.3 0.13
140.3  25.8 137.9  25.4 0.57
59.0  9.5 58.9  9.7 0.31
. *The trend test refers to a 1-degree of freedom test for linear trend across quartiles.
R ¼ estimated glomerular ﬁltration rate; FGF ¼ ﬁbroblast growth factor; LVEF ¼ left ventricular
blood pressure; RU ¼ reference units.
Figure 1
Cumulative Incidence Curves for the Composite of
Cardiovascular Death or Heart Failure Among
Patients in the Placebo Arm (n ¼ 1,815)
Patients are categorized by quartiles of ﬁbroblast growth factor (FGF)-23. The
p value is for log-rank test for trend across quartiles.
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2424the strongest correlations being with cystatin C and midre-
gional pro-adrenomedullin (rho 0.36 and 0.39, respectively,
p < 0.001 for both) (Online Table 2).
FGF-23 levels and clinical endpoints. Among 1,815
placebo-assigned patients, 114 experienced cardiovascular
death or incident heart failure over a median 5.1 years of
follow-up. Higher baseline levels of FGF-23 were strongly
associated with the subsequent risk of cardiovascular death or
heart failure, with a 35% increased risk per 1-SD increase
in log-transformed FGF-23 levels (HR: 1.35; 95% CI: 1.20
to 1.53; p < 0.0001). Risk increased across quartiles of FGF-
23, particularly among patients who were in the highest
quartile of FGF-23 (HR: 3.32; 95% CI: 1.95 to 5.66;
p < 0.0001) (Fig. 1). A similar pattern was seen for the
individual endpoints of cardiovascular death and heart failure
(HR: 3.16; 95% CI: 1.54 to 6.49; p ¼ 0.0009, and HR: 4.44;
95% CI: 2.04 to 9.63; p < 0.0001, respectively) (Online
Table 3). As expected on the basis of prior work (6,7),
FGF-23 was not associated with the incidence of MI, stroke,
unstable angina, or coronary revascularization (Online Table 3).
After adjustment for traditional clinical risk factors
(age, sex, weight, hypertension, diabetes mellitus, currentTable 2 Association of FGF-23 Levels and Clinical Outcomes in the P
Outcome
HR (95% CI) per 1-SD Increase in
Log-Transformed FGF-23 p Value
1
(<38.81)
CV death, HF 1.31 (1.13–1.51) 0.0004 Referent
CV death 1.35 (1.11–1.63) 0.002 Referent
HF 1.36 (1.12–1.66) 0.002 Referent
*Covariates in the model include conventional clinical factors: age, sex, weight, history of hypertension
coronary intervention or coronary artery bypass graft surgery, systolic blood pressure, estimated glome
to a 1-degree of freedom test for linear trend across quartiles. yPlasma FGF-23 concentrations are repo
CI ¼ conﬁdence interval; CV ¼ cardiovascular; FGF ¼ ﬁbroblast growth factor; HF ¼ heart failure; HRtobacco use, prior MI, prior coronary revascularization, and
systolic blood pressure), eGFR, and left ventricular ejection
fraction, elevated concentrations of FGF-23 remained
independently associated with an increased risk of cardio-
vascular death or heart failure per 1-SD increase (adjusted
HR: 1.31; 95% CI: 1.13 to 1.51; p ¼ 0.0004). Quartile
analysis demonstrated that the independent association
between higher levels of FGF-23 and the incidence of
cardiovascular death or heart failure was evident in those
patients in the top quartile of FGF-23 levels (adjusted
HR: 2.31; 95% CI: 1.32 to 4.05; p ¼ 0.003) as was the risk
of cardiovascular death or heart failure individually
(Table 2). The addition of FGF-23 to the clinical model
signiﬁcantly improved metrics of discrimination, including
an improvement in the C-statistic from 0.764 (95% CI:
0.718 to 0.810) to 0.784 (95% CI: 0.740 to 0.829), an
integrated discrimination improvement of 1.65%, and a net
reclassiﬁcation improvement of 0.43 (all p < 0.05).
In addition to eGFR, the risk associated with elevated
FGF-23 levels was additive to and independent of other
biomarkers of renal function, including cystatin C and uri-
nary ACR, with comparable elevated risk of cardiovascular
death or heart failure in patients with levels in the highest
category of either FGF-23 or another renal biomarker, and
markedly elevated risk among patients presenting in the
highest risk category of both biomarkers simultaneously
(Fig. 2). Moreover, in multivariable analyses adjusting for
clinical characteristics, eGFR, cystatin C, and urinary ACR,
patients with an FGF-23 level in the fourth quartile still
had a 2-fold elevation in risk for cardiovascular death or heart
failure (adjusted HR: 2.00; 95% CI: 1.28 to 3.14; p ¼ 0.003)
compared to those in quartiles 1 through 3. Furthermore,
FGF-23 in the top quartile was an independent risk factor
for cardiovascular death or heart failure even when evaluated
in patients with normal renal function as deﬁned by
GFR 60 ml/min/1.73 m2 (HR: 2.54; 95% CI: 1.59 to
4.07; p < 0.0001), cystatin C <0.91 mg/l (HR: 2.26; 95%
CI: 1.20 to 4.24; p ¼ 0.011), or absence of microalbuminuria
(HR: 2.20; 95% CI: 1.10 to 4.38; p ¼ 0.025).
We next assessed whether FGF-23 remained a signiﬁcant
predictor of risk after adjusting for well-established cardio-
vascular biomarkers, speciﬁcally NT-proBNP, hs-cTnT,
and hs-CRP. Even after adding all 3 of these biomarkers to
a model adjusted for the aforementioned clinical covariateslacebo Arm Adjusted for Clinical Findings at Baseline*
HR (95% CI) Across Quartiles (RU/ml Range)y
p Value
for Trend
2
(38.81–50.05)
3
(50.06–70.20)
4
(>70.20)
0.75 (0.38–1.50) 1.07 (0.58–1.98) 2.31 (1.32–4.05) 0.002
0.92 (0.39–2.19) 1.20 (0.53–2.70) 2.14 (1.003–4.57) 0.038
0.64 (0.21–1.97) 1.07 (0.43–2.69) 3.28 (1.46–7.38) 0.0003
, history of diabetes mellitus, current tobacco use, prior myocardial infarction, prior percutaneous
rular ﬁltration rate, and left ventricular ejection fraction. In quartile analyses, a trend test refers
rted in reference units (RU)/ml.
¼ hazard ratio; RU ¼ reference units.
Figure 2
6-Year Incidence Rates for the Composite of
Cardiovascular Mortality or Heart Failure in Placebo
Patients Stratiﬁed by FGF-23, and Either eGFR,
Cystatin C, or Microalbuminuria
Patients are categorized dichotomously according to whether their level of FGF-23
was in the top quartile (high) or not (low) and their eGFR was <60 ml/min/1.73 m2
or not (A) and their cystatin C level was in the top quartile (0.91 mg/l: high) or
not (<0.91 mg/l: low) (B), and by the presence or absence of microalbuminuria
(urinary albumin to creatinine ratio of 25 mg/mg in women and 17 mg/mg in
men) (C). P values in ﬁgure represent global p value for differences in rates.
Furthermore, for all pairwise comparisons p < 0.05. eGFR ¼ estimated glomerular
ﬁltration rate; FGF ¼ ﬁbroblast growth factor.
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2425and biomarkers of renal function, FGF-23 levels in the top
quartile remained a signiﬁcant independent predictor of
cardiovascular death or heart failure (adjusted HR: 1.73;
95% CI: 1.09 to 2.74; p ¼ 0.02). Midregional pro-atrial
natriuretic peptide and midregional pro-adrenomedullin
are alternative biomarkers of cardiovascular stress (21).
Starting with a model that contained the aforementioned
clinical covariates, biomarkers of renal function, and estab-
lished cardiovascular biomarkers, applying a forward selec-
tion algorithm to FGF-23, midregional pro-atrial natriuretic
peptide and midregional pro-adrenomedullin resulted in
only FGF-23 achieving signiﬁcance and entering and stay-
ing in the model (p ¼ 0.02).
Interaction with trandolapril therapy. We observed a
signiﬁcant interaction between FGF-23 levels and the effect
of trandolapril with respect to cardiovascular mortality or
heart failure (p interaction ¼ 0.0039). Among patients
treated with trandolapril, there was not a gradient of risk with
increasing FGF-23 levels, and consequently, among patients
in the top quartile of FGF-23, trandolapril signiﬁcantly
reduced the risk of cardiovascular death or heart failure by
55% (HR: 0.45; 95% CI: 0.28 to 0.72) (Fig. 3), whereas no
beneﬁt was observed in patients with lower levels of FGF-23
(HR: 1.07; 95% CI: 0.75 to 1.52). Similar trends were
observed for the individual risk of cardiovascular death and
heart failure events (Online Table 4). The absolute risk
reduction with ACE inhibitor therapy over 6 years among
patients with SIHD in the highest risk category of FGF-23
was 8.62%, representing a number-needed-to-treat of 12
patients to prevent one additional cardiovascular death or
incident heart failure. Furthermore, the gradient of clinical
beneﬁt with trandolapril deﬁned by an elevated FGF-23 level
was additive to that seen using renal function (Online Fig. 1)
or biomarkers of cardiovascular stress (Online Fig. 2). There
was no interaction among FGF-23 levels, trandolapril ther-
apy, and atherothrombotic events (Online Table 5).
Discussion
The results of this investigation support the hypothesis that
higher levels of FGF-23 are associated with cardiovascular
mortality and incident heart failure in patients with SIHD.
Of note, akin to what has been observed for hs-CRP (25),
risk was seen with plasma FGF-23 levels well within the
observed range in the general population without known
cardiovascular disease or renal impairment (7,15). We
also show that FGF-23 provides incremental prognostic in-
formation even after adjusting for clinical risk factors, renal
function, and cardiovascular biomarkers. Lastly, leveraging
data from a randomized controlled trial, we demonstrate that
patients with higher levels of FGF-23 received clinical beneﬁt
from ACE inhibitor therapy, independent of renal function.
FGF-23 is a phosphatonin that is synthesized and
secreted by osteoblasts into the circulation. At normal levels,
FGF-23 acts primarily in the kidney to maintain phosphate
homeostasis by inducing urinary phosphate excretion(26,27). Elevated FGF-23 levels have previously been
associated with progression of renal dysfunction and mor-
tality in patients with CKD (4,5,28). However, when
examining the association of FGF-23 levels with
Udell et al. JACC Vol. 63, No. 22, 2014
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2426cardiovascular outcomes in patients without CKD, the re-
sults have been less clear. One study in 833 patients with
SIHD did show an association between FGF-23 levels and
mortality, but there was no adjustment for established car-
diovascular biomarkers such as B-type natriuretic peptide
and cardiac troponin (6). In studies of community-dwelling
individuals with a low prevalence of or no known coronary
disease, associations between FGF-23 levels and major
adverse cardiovascular events were either absent (7) or
severely attenuated after adjustment for renal function (8,9).
To our knowledge, this is the ﬁrst report to demonstrate
that in patients with stable coronary disease, the adverse
cardiovascular risk associated with higher levels of FGF-23 is
independent of renal function, whether deﬁned using eGFR,
cystatin C, or microalbuminuria, and signiﬁcant even in
those with normal renal function as deﬁned using the pre-
viously described markers. Moreover, we show that FGF-23
remains an independent prognostic factor even after
adjusting for established cardiovascular biomarkers including
NT-proBNP, hs-cTnT, and hs-CRP.
In addition to deﬁning a population at high risk for
adverse cardiovascular prognosis, the results of this study
also support the hypothesis that elevated FGF-23 levels
identify a population in whom ACE inhibitor therapy was
effective at lowering this risk. These ﬁndings build on our
previous work demonstrating that ACE inhibition yielded
greater clinical beneﬁts among patients with SIHD who
have evidence of renal dysfunction deﬁned as a low eGFR
(11,12). Importantly, FGF-23 and eGFR offered additive
stratiﬁcation in terms of the clinical beneﬁt of ACE inhi-
bition, suggesting they provide complementary value.
There are several possible pathobiological explanations for
the association between elevated circulating levels of FGF-23Figure 3
Cumulative Incidence Curves for the Composite of Cardiova
FGF-23 Level and Treatment With Trandolapril
Red lines indicate patients with high FGF-23 levels (>70.20 RU/ml): the solid line indica
treated with trandolapril (n ¼ 451). Blue lines indicate patients with low FGF-23 levels (7
the dashed line indicates patients treated with trandolapril (n ¼ 1,361). CI ¼ conﬁdenceand the risk of cardiovascular death and incident heart failure
as opposed to atherothrombotic events. Elevated levels of
FGF-23 may be an early marker of subclinical renal disease
(1–3,28), and/or disrupted mineral homeostasis, each of
which might lead to cardiovascular toxicity. However, given
the observed prognostic signiﬁcance independent of multiple
established renal biomarkers, one must consider that FGF-
23 may have direct links to the cardiovascular system. To
that end, there are FGF receptors in the heart (29). The near
absence of Klotho (a necessary coreceptor for FGF-23 in the
distal renal tubule) (30,31) in the heart had previously led to
the assumption that FGF-23 could not mediate any direct
cardiac effects. Challenging that notion, however, in-
vestigators have shown that, via calcineurin/nuclear factor of
activated T-cells pathways independent of Klotho, FGF-23
can induce myocyte hypertrophy and left ventricular hyper-
trophy in animal models (32,33). Furthermore, clinical
studies have demonstrated that FGF-23 is independently
associated with adverse left ventricular remodeling and is an
independent predictor of survival in patients with established
heart failure (32,34–38). Investigators have recently demon-
strated the presence of Klotho in the human vasculature
where it, and as a result, FGF-23 indirectly, appears to exert
anticalciﬁc effects (39,40). However, in our study there were
only nonsigniﬁcant trends for an association between FGF-
23 levels in the highest quartile and the risk of MI and
stroke, consistent with weak or absent associations seen in
other studies (6–8,10).
Data are also emerging for the link between FGF-23,
Klotho, and the renin-angiotensin system. Speciﬁcally,
angiotensin II negatively regulates Klotho expression (41),
which, in turn, would result in a compensatory increase in
FGF-23 levels. Furthermore, FGF-23 directly suppressesscular Death or Heart Failure in Patients Categorized by
tes patients treated with placebo (n ¼ 455); and the dashed line indicates patients
0.20 RU/ml): the solid line indicates patients treated with placebo (n ¼ 1,360); and
interval; FGF ¼ ﬁbroblast growth factor; HR ¼ hazard ratio.
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Unlike ACE, ACE2 is a negative regulator of the renin-
angiotensin system, promoting vasodilation and natriuresis
(43). Thus, one can speculate that patients with higher
levels of angiotensin II would have relative suppression
of Klotho and increased circulating FGF-23 levels, with
resultant left ventricular hypertrophy, vascular stiffness, and
ACE2-induced activation of the renin-angiotensin system,
all of which would contribute to an increased risk of car-
diovascular death or heart failure rather than contributing
to progressive or unstable atherosclerotic plaque. ACE in-
hibition would then be particularly beneﬁcial in this setting.
Study limitations. This analysis was performed in a selec-
tion of patients participating in a clinical trial rather than
from the general population; however, the demographics and
clinical characteristics of the cohort are typical for patients
with SIHD. It should be noted that cardiovascular death and
heart failure were not the primary endpoint of the parent
clinical trial; however, they were the outcomes most strongly
associated with FGF-23 levels in prior studies, have been
shown to be reduced by ACE inhibition, and thus were the
logical choice to examine for the prognostic value of FGF-
23 and for a treatment interaction. Although we did not
have data on parathyroid hormone, phosphate, calcium, or
vitamin D levels, we controlled for eGFR, cystatin C, and
urinary ACR, renal biomarkers strongly associated with
these substances. Moreover, there is no clear evidence sup-
porting an independent association between mineral levels
and cardiovascular events, especially in patients without
CKD (44). We do not have data on renin and angiotensin II
levels, which are optimally assessed on fresh samples, and
have no data on the modiﬁability of FGF-23 levels over time
in this study. Major strengths of our study include its robust
sample size and number of observed clinical events; detailed
collection of subjects’ clinical and laboratory data; risk esti-
mation with consideration of clinical risk factors and con-
ventional markers of cardiac and renal function; and
randomization of medical therapy allowing for an unbiased
measure of clinical effectiveness stratiﬁed by baseline risk.
Nevertheless, studies in other populations are welcome to
conﬁrm our ﬁndings.
Conclusions
Elevated levels of the phosphatonin FGF-23 were inde-
pendently associated with cardiovascular death and incident
heart failure in patients with SIHD. Trandolapril therapy
signiﬁcantly attenuated this relationship. These observations
suggest this novel biomarker may be helpful in estimating
future cardiovascular risk and help to predict the response to
ACE inhibitor therapy in patients with SIHD.
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